Answers are grounded in this paper and cite their sources.
Observational analysis identifies FPSIR as a biomarker predicting survival in mCRC patients, suggesting improved treatment strategies.
Pretreatment FPSIR was identified as a robust biomarker for predicting clinical efficacy and prognosis in mCRC patients receiving first-line Bev/CT, providing a promising strategy to address the long-standing challenge of treatment stratification.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: